183 related articles for article (PubMed ID: 35695781)
21. Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population.
Kilpatrick RD; Chiuve SE; Leslie WD; Wegrzyn LR; Gao W; Yang H; Soliman AM; Snabes MC; Koenigsberg S; Zhong J; Xiang C; Watts NB
JBMR Plus; 2020 Dec; 4(12):e10401. PubMed ID: 33354641
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
23. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
24. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
Arjona Ferreira JC; Migoya E
F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
[TBL] [Abstract][Full Text] [Related]
25. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.
Neri M; Melis GB; Giancane E; Vallerino V; Pilloni M; Piras B; Loddo A; Paoletti AM; Mais V
Int J Womens Health; 2019; 11():535-546. PubMed ID: 31695514
[TBL] [Abstract][Full Text] [Related]
27. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
[TBL] [Abstract][Full Text] [Related]
28. Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.
Ng J; Chwalisz K; Carter DC; Klein CE
J Clin Endocrinol Metab; 2017 May; 102(5):1683-1691. PubMed ID: 28323948
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review.
Niaz R; Saeed M; Khan H; Ali MA; Irshad A; Faiz M; Irshad A; Fatima F; Tunio SA; Aiman W
J Obstet Gynaecol Can; 2022 Dec; 44(12):1279-1288. PubMed ID: 36368594
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of [H-3]- and [C-14]-labeled elagolix.
Soli ED; Surber BW; Reed AD
J Labelled Comp Radiopharm; 2021 Jun; 64(7):254-261. PubMed ID: 33675109
[TBL] [Abstract][Full Text] [Related]
31. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
32. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists.
de Lange ME; Semmler A; Clark TJ; Mol BWJ; Bet PM; Huirne JAF; Hehenkamp WJK
Br J Clin Pharmacol; 2024 Feb; 90(2):392-405. PubMed ID: 37653680
[TBL] [Abstract][Full Text] [Related]
33. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Neblett MF; Stewart EA
Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
[TBL] [Abstract][Full Text] [Related]
34. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
35. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
36. Elagolix, Estradiol, and Norethindrone Kit (Oriahnn) for the Management of Heavy Menstrual Bleeding Associated with Fibroids.
Antoun J
Am Fam Physician; 2021 Apr; 103(8):505-506. PubMed ID: 33856165
[No Abstract] [Full Text] [Related]
37. Oriahnn for fibroid-associated heavy menstrual bleeding.
Med Lett Drugs Ther; 2021 Apr; 63(1621):51-52. PubMed ID: 33830967
[No Abstract] [Full Text] [Related]
38. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
[TBL] [Abstract][Full Text] [Related]
39. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
40. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
Ali M; Raslan M; Ciebiera M; Zaręba K; Al-Hendy A
Expert Opin Drug Saf; 2022 Apr; 21(4):477-486. PubMed ID: 34612122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
